HM Payson & Co. Sells 20,885 Shares of Thermo Fisher Scientific Inc. $TMO

HM Payson & Co. decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.3% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 163,790 shares of the medical research company’s stock after selling 20,885 shares during the quarter. Thermo Fisher Scientific makes up 1.1% of HM Payson & Co.’s portfolio, making the stock its 21st biggest holding. HM Payson & Co.’s holdings in Thermo Fisher Scientific were worth $82,118,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $7,505,000. Boston Trust Walden Corp raised its stake in Thermo Fisher Scientific by 9.7% during the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock worth $25,480,000 after acquiring an additional 3,873 shares during the period. Xponance LLC lifted its holdings in Thermo Fisher Scientific by 8.1% during the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock valued at $34,358,000 after purchasing an additional 4,436 shares in the last quarter. Hudson Value Partners LLC increased its stake in shares of Thermo Fisher Scientific by 24.9% in the second quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company’s stock worth $8,349,000 after purchasing an additional 3,317 shares in the last quarter. Finally, Merit Financial Group LLC raised its position in shares of Thermo Fisher Scientific by 34.0% during the 4th quarter. Merit Financial Group LLC now owns 15,504 shares of the medical research company’s stock valued at $8,984,000 after purchasing an additional 3,934 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock worth $30,643,589 in the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Piper Sandler upped their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Royal Bank Of Canada lifted their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research note on Friday, July 24th. Finally, Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $588.17 on Friday. The company’s 50-day moving average price is $529.37 and its 200-day moving average price is $509.58. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market cap of $217.47 billion, a PE ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.85. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter last year, the firm earned $4.28 EPS. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.